~~<i id='EFDDB2466D'><strike id='EFDDB2466D'><tt id='EFDDB2466D'><pre id='EFDDB2466D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

hotspot

author：hotspot 2025-09-30 08:53:19 - browse：91598

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Why don't Americans have at

entertainment

leisure time

knowledge

hotspot

KristofferTripplaar/APEventually,theluckiestcompaniesgettodealwithaveryparticularproblem:whattodowhe

WSS

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Congress considering partial increase for doctor pay in Medicare

AMAs digital advisors table RPM coding reform proposal, again

Tome Biosciences co

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

ACIP vaccine advisory panel sees its vacancies filled

knowledge

hotspot

entertainment

What does generative AI mean for health care? We asked experts

Tome Biosciences co

Duchenne breakthrough therapy leaves behind pioneering families

Hospitals look to new technology to keep health care workers safe

The high cost of giving birth even with insurance

Astellas still sees hope in its gene therapy after four deaths

Jerome Adams on the need for new antivirals for Covid

Report cites 'urgent' need to recruit more diverse clinical trial participants

Affirmative action in medical school literally saved lives

Resistance to opioid

entertainment

Weight loss drug costs may need more research, senator suggests

Juul documents reveal insider tactics on political lobbying

Juul documents reveal insider tactics on political lobbying

Wegovy, Zepbound and weight loss drugs that preserve muscle

Latigo launches with $135 million for Vertex

Congress must reauthorize a committee to support older Americans

leisure time

knowledge

hotspot

hotspot